Sign in

CIK 0001348362

  • Non-accelerated filer
  • Smaller reporting company

Lexaria Bioscience Corp.

Sign in to watch
Ticker
LEXX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Aug 31
Incorporated
NV
Entity type
Operating
EIN
202000871
Phone
+1 250-765-6424
Business address
100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
Former names
Lexaria Corp., LEXARIA CORP.
  1. 4 Open-market buy CEO bought 15,000 shares at an average $0.21 ($3,188)
  2. 4 Open-market buy CEO bought 16,600 shares at an average $0.21 ($3,416)
  3. 4 Derivatives Options or other derivatives
  4. 4 Open-market buy CEO bought 44,000 shares at an average $0.21 ($9,068)
  5. 4 Open-market buy CEO bought 36,000 shares at an average $0.21 ($7,430)
  6. 4 Open-market buy CEO bought 29,000 shares at an average $0.19 ($5,563)
  7. 4 Open-market buy CEO bought 17,570 shares at an average $0.19 ($3,399)
  8. 4 Open-market buy CEO bought 25,000 shares at an average $0.21 ($5,336)
  9. 4 Open-market buy CEO bought 12,500 shares at an average $0.18 ($2,220)
  10. 4 Open-market buy CEO bought 19,000 shares at an average $0.18 ($3,459)
  11. 4 Open-market buy CEO bought 32,110 shares at an average $0.18 ($5,799)
  12. 4 Open-market buy CEO bought 16,900 shares at an average $0.19 ($3,159)
  13. 4 Open-market buy CEO bought 81,500 shares at an average $0.18 ($15,037)
  14. 4 Open-market buy CEO bought 10,000 shares at an average $0.18 ($1,845)
  15. 4 Open-market buy CEO bought 23,000 shares at an average $0.18 ($4,164)
  16. 4 Open-market buy CEO bought 99,800 shares at an average $0.18 ($17,920)
  17. 4 Open-market buy CEO bought 59,256 shares at an average $0.18 ($10,559)
  18. 4 Open-market buy CEO bought 46,400 shares at an average $0.17 ($8,005)
  19. 4 Open-market buy CEO bought 66,750 shares at an average $0.17 ($11,614)
  20. 4 Open-market buy CEO bought 188,404 shares at an average $0.17 ($32,247)

Page 10 of 21 · 420 filings